National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Naltrexone / bupropion (Mysimba®) is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.

 

NCPE Assessment Process Ongoing
Rapid review received 12/03/2017
Rapid review completed 28/03/2017
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE 29/03/2017
Pre-submission consultation with Applicant 29/05/2017
Submission received from Applicant 06/11/2017
Preliminary review sent to Applicant 05/01/2018
NCPE assessment re-commenced 01/02/2018
Current Status NCPE assessment ongoing